Stockreport

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial AstraZeneca and Daiichi Sankyo's ENHERTU also demonstrated a clinica [Read more]